Literature DB >> 11170950

Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly.

D N Fisman1, D T Reilly, A W Karchmer, S J Goldie.   

Abstract

Optimal management of infected total hip arthroplasty poses a major challenge to clinicians. Exchange arthroplasty is usually advocated but has high rates of surgical morbidity and is expensive. Debridement with prosthesis retention is associated with less morbidity, but high rates of relapsed infection have been described. To estimate the effectiveness and cost-effectiveness of these 2 strategies among older patients, we used a Markov model to simulate patients' projected lifetime clinical course in hypothetical cohorts of 65-year-old and frail 80-year-old men and women. Initial debridement and retention increased life expectancy 2.2-2.6 quality-adjusted life months and had a favorable cost-effectiveness ratio in all cohorts. Results were most sensitive to the annual rate of relapse after debridement and age at initial diagnosis of infection. In the absence of prospective clinical trials, debridement and retention is a reasonable strategy for treatment of older persons with staphylococcal or streptococcal infection and a nonloosened prosthesis.

Entities:  

Mesh:

Year:  2001        PMID: 11170950     DOI: 10.1086/318502

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  40 in total

1.  Infections Associated with Prosthetic Knee and Prosthetic Hip.

Authors:  Joseph R Lentino
Journal:  Curr Infect Dis Rep       Date:  2004-10       Impact factor: 3.725

2.  Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.

Authors:  O C El Helou; E F Berbari; B D Lahr; J E Eckel-Passow; R R Razonable; I G Sia; A Virk; R C Walker; J M Steckelberg; W R Wilson; A D Hanssen; D R Osmon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-27       Impact factor: 3.267

3.  Two-stage revision of prosthetic hip joint infections using antibiotic-loaded cement spacers: When is the best time to perform the second stage?

Authors:  Ines Vielgut; Patrick Sadoghi; Matthias Wolf; Lukas Holzer; Andreas Leithner; Gerold Schwantzer; Rudolf Poolman; Bernhard Frankl; Mathias Glehr
Journal:  Int Orthop       Date:  2015-04-14       Impact factor: 3.075

Review 4.  [Revision strategy for periprosthetic infection].

Authors:  B Lehner; D Witte; A J Suda; S Weiss
Journal:  Orthopade       Date:  2009-08       Impact factor: 1.087

Review 5.  [Classification of prosthetic loosening and determination of wear particles].

Authors:  M Otto
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 6.  Current status of cost utility analyses in total joint arthroplasty: a systematic review.

Authors:  Benedict U Nwachukwu; Kevin J Bozic; William W Schairer; Jaime L Bernstein; David S Jevsevar; Robert G Marx; Douglas E Padgett
Journal:  Clin Orthop Relat Res       Date:  2014-09-30       Impact factor: 4.176

7.  What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis.

Authors:  Thomas J Parisi; Joseph F Konopka; Hany S Bedair
Journal:  Clin Orthop Relat Res       Date:  2017-04-07       Impact factor: 4.176

8.  Assessing the value of a total joint replacement.

Authors:  David B Bumpass; Ryan M Nunley
Journal:  Curr Rev Musculoskelet Med       Date:  2012-12

9.  Clinical spectrum and outcome of critically ill patients suffering from prosthetic joint infections.

Authors:  Y Maaloum; A Meybeck; D Olive; N Boussekey; P-Y Delannoy; A Chiche; H Georges; E Beltrand; E Senneville; T d'Escrivan; O Leroy
Journal:  Infection       Date:  2012-10-25       Impact factor: 3.553

Review 10.  Functional outcomes of acutely infected knee arthroplasty: a comparison of different surgical treatment options.

Authors:  Ivan Dzaja; James Howard; Lyndsay Somerville; Brent Lanting
Journal:  Can J Surg       Date:  2015-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.